Transgenic tumor models for carcinogen identification: The heterozygous Trp53-deficient and RasH2 mouse lines

Mutation Research - Genetic Toxicology and Environmental Mutagenesis

Volumn 540, Issue 2, 2003, Pages 165-176

  Storer, R D ^a   French, J E ^b   Donehower, L A ^c   Gulezian, D ^d   Mitsumori, K ^e   Recio, L ^a   Schiestl, R H ^f   Sistare, F D ^g   Tamaoki, N ^h   Usui, T ^h   Van Steeg, H ⁱ  

^a MERCK RESEARCH LABORATORIES   (United States)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d Taconic Farms Inc   (United States)

^e TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY   (Japan)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^h CENTRAL INSTITUTE FOR EXPERIMENTAL ANIMALS   (Japan)

ⁱ NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

Carcinogen; Genetically altered mouse model; Rodent

Indexed keywords

CARCINOGEN; PROTEIN P53; RAS PROTEIN;

ALLELE; CANCER; CARCINOGENESIS; CARCINOGENICITY; DNA MODIFICATION; GENE INTERACTION; GENETIC ANALYSIS; HETEROZYGOSITY; MAXIMUM TOLERATED DOSE; MOLECULAR BIOLOGY; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR MODEL;

ANIMALIA; RODENTIA;

EID: 0141785151     PISSN: 13835718     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrgentox.2003.07.006     Document Type: Article

References (53)

1. International Conference on Harmonization, guidance on testing for carcinogenicity of pharmaceuticals, Fed. Reg. 63 (1998) 8983-8986.
2. ILSI/HESI alternatives to carcinogenicity project, Toxicol. Pathol. 29 (Suppl.) (2001) 1-351.
3. Tamaoki N. The rasH2 transgenic mouse: nature of the model and mechanistic studies on tumorigenesis. Toxicol. Pathol. 29(Suppl.):2001;81-89.
4. French J., Storer R.D., Donehower L. The nature of the heterozygous Trp53 knockout model for identification of mutagenic carcinogens. Toxicol. Pathol. 29(Suppl.):2001;24-29.
5. Weaver J.L., Contrera J.F., Rosenzweig B.A., Thompson K.L., Faustino P.J., Strong J.M., Ellison C.D., Anderson L.W., Prasanna H.R., Long-Bradley P.E., Lin K.K., Zhang J., Sistare F.D. An evaluation of the hemizygous transgenic Tg.AC mouse for carcinogenicity testing of pharmaceuticals. I. Evidence for a confounding nonresponder phenotype. Toxicol. Pathol. 26(4):1998;532-540.
6. Thompson K.L., Rosenzweig B.A., Sistare F.D. An evaluation of the hemizygous transgenic Tg.AC mouse for carcinogenicity testing of pharmaceuticals. II. A genotypic marker that predicts tumorigenic responsiveness. Toxicol. Pathol. 26(4):1998;548-555.
7. Honchel R., Rosenzweig B.A., Thompson K.L., Blanchard K.T., Furst S.M., Stoll R.E., Sistare F.D. Loss of palindromic symmetry in Tg.AC mice with a nonresponder phenotype. Mol. Carcinog. 30(2):2001;99-110.
8. Thompson K.L., Rosenzweig B.A., Honchel R., Cannon R.E., Blanchard K.T., Stoll R., Sistare F.D. Loss of critical palindromic transgene promoter sequence in chemically induced Tg.AC mouse skin papillomas expressing transgene-derived mRNA. Mol. Carcinog. 32(4):2001;176-186.
9. Gulezian D., Lohmiller J., Roberts A., Arlund R.E., Vitale J., Meyer T., Shields K., Bower M., Gunther R., Navins D. Correlation of genotype with a phenotype to quality control and stabilize the responder transgene in a production colony of Tg.AC transgenic mice. Toxicol. Pathol. 29(Suppl.):2001;310-311.
10. Saitoh A., Kimura M., Takahashi R., Yokoyama M., Nomura T., Izawa M., Sekiya T., Nishimura S., Katsuki M. Most tumors in transgenic mice with human c-Ha-ras gene contained somatically activated transgenes. Oncogene. 5:1990;1195-1200.
11. Suemizu H., Muguruma K., Maruyama C., Tomisawa M., Kimura M., Hioki K., Shimozawa N., Ohnishi Y., Tamaoki N., Nomura T. Transgene stability and features of rasH2 mice as an animal model for short-term carcinogenicity testing. Mol. Carcinog. 34(1):2002;1-9.
12. Rosenzweig B.A., Curtiss S.W., Sistare F.D. Two genotyping approaches to assuring quality control of transgene stability in the TgrasH2 transgenic mouse. Toxicologist. 60:2001;280.
13. N. Tamaoki, Nature of the rasH2 Model, Presentation at the Third International Workshop on Genotoxicity Testing, Plymouth, UK, 2002.
14. D. Gulezian, Quality Assurance Program: Taconic Transgenic Model TSG-p53, Presentation at the Third International Workshop on Genotoxicity Testing, Plymouth, UK, 2002.
15. Donehower L.A., Harvey M., Vogel H., McArthur M.J., Montgomery C.A. Jr., Park S.H., Thompson T., Ford R.J., Bradley A. Effects of genetic background on tumorigenesis in p53-deficient mice. Mol. Carcinogen. 14:1995;16-22.
16. Dunnick J.K., Hardisty J.F., Herbert R.A., Seely J.C., Furedi-Machacek E.M., Foley J.F., Lacks G.D., Stasiewicz S., French J.E. Phenolphthalein induces thymic lymphomas accompanied by loss of the p53 wild type allele in heterozygous p53-deficient (+/-) mice. Toxicol. Pathol. 25:1997;533-540.
17. Okamura M., Kashida Y., Watanabe T., Yasuhara K., Onodera H., Hirose M., Usui T., Tamaoki N., Mitsumori K. Lack of susceptibility of heterozygous p53-knockout CBA and CIEA mice to phenolphthalein in a 6-month carcinogenicity study. Toxicology. 185(1/2):2003;17-22.
18. Jacks T., Remmington L., Williams B.O., Schmidt E.M., Halachmi S., Bronson R., Weinberg R.A. Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 4(1):1994;1-7.
19. van-Steeg H., de-Vries A., van-Oostrom C.Th., van-Benthem J., Beems R.B., van-Kreijl C.F. DNA repair-deficient Xpa and Xpa/p53+/- knock-out mice: nature of the models. Toxicol. Pathol. 29(Suppl.):2001;109-116.
20. Donehower L.A., Harvey M., Slagle B.L., McArthur M.J., Montgomery C.A. Jr., Butel J.S., Bradley A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature. 356:1992;215-221.
21. Venkatachalam S., Shi Y.P., Jones S.N., Vogel H., Bradley A., Pinkel D., Donehower L.A. Retention of wild type p53 in tumors from p53 heterozygous mice: reduction of p53 gene dosage can promote cancer formation. EMBO J. 17(16):1998;4657-4667.
22. Venkatachalam S., Tyner S.D., Pickering C.R., Boley S., Recio L., French J.E., Donehower L.A. Is p53 haploinsufficient for tumor suppression? Implications for the p53+/- mouse model in carcinogenicity testing. Toxicol. Pathol. 29(Suppl.):2001;147-154.
23. Boley S.E., Wong V.A., French J.E., Recio L. p53 heterozygosity alters the mRNA expression of p53 target genes in the bone marrow in response to inhaled benzene. Toxicol. Sci. 66(2):2002;209-215.
24. Ando K., Saitoh A., Hino O., Takahashi R., Kimura M., Katsuki M. Chemically induced forestomach papillomas in transgenic mice carry mutant human c-Ha-ras transgenes. Cancer Res. 52:1992;978-982.
25. Doi S.T., Kimura M., Katsuki M. Site-specific mutation of the human c-Ha-ras transgene induced by dimethylbenzanthracene causes tissue-specific tumors in mice. Jpn. J. Cancer Res. 85(8):1994;801-807.
26. Ogawa K., Imaida K., Masui T., Kawabe M., Hasegawa R., Kato K., Ito N., Shirai T. Chemically induced lung and forestomach neoplasias in transgenic mice carry mutant forms of the human c-Ha-ras transgene. Carcinogenesis. 17(2):1996;341-345.
27. Mitsumori K., Wakana S., Yamamoto S., Kodama Y., Yasuhara K., Nomura T., Hayashi Y., Maronpot R.R. Susceptibility of transgenic mice carrying human prototype c-Ha-ras gene in a short-term carcinogenicity study of vinyl carbamate and ras gene analyses on the induced tumors. Mol. Carcinogen. 20:1997;298-307.
28. T. Usui, CB6F1-ras H2 Mouse: Overview of Available Data, Presentation at the Third International Workshop on Genotoxicity Testing, Plymouth, UK, 2002.
29. Maruyama C., Tomisawa M., Wakana S., Yamazaki H., Hijima H., Suemizu H., Ohnishi Y., Urano K., Hioki K., Usui T., Nakamura M., Tsuchida T., Mitsumori K., Nomura T., Tamaoki N., Ueyama Y. Overexpression of human H-ras transgene is responsible for tumors induced by chemical carcinogens in mice. Oncol. Reports. 8:2001;233-237.
30. Kemp C.J., Wheldon T., Balmain A. p53-deficient mice are extremely susceptible to radiation-induced tumorigenesis. Nat. Genet. 8:1994;66-69.
31. Ozaki K., Sukata T., Yamamoto S., Uwagawa S., Seki T., Kawaski H., Yoshitake A., Wanibuchi H., Koide A., Mori Y., Fukushima S. High susceptibility of p53(+/-) knockout mice in n-butyl-N-(4-hydroxybutyl)nitrosamine urinary bladder carcinogenesis and lack of frequent mutation in residual allele. Cancer Res. 58(17):1998;3806-3811.
32. French J.E., Lacks G.D., Trempus C., Dunnick J.K., Foley J., Mahler J., Tice R.R., Tennant R.W. Loss of heterozygosity frequency at the Trp53 locus in p53-deficient (+/-) mouse tumors is carcinogen-and tissue-dependent. Carcinogenesis. 22(1):2001;99-106.
33. Boley S.E., Anderson E.E., French J.E., Donehower L.A., Walker D.B., Recio L. Loss of p53 in benzene-induced thymic lymphomas in p53+/- mice: evidence of chromosomal recombination. Cancer Res. 60(11):2000;2831-2835.
34. L. Recio, Genotoxic Stress Response in the Bone Marrow and Tumor Development in p53 Heterozygous Mice Exposed to Inhaled Benzene. Presentation at the Third International Workshop on Genotoxicity Testing, Plymouth, UK, 2002.
35. Hulla J.E., French J.E., Dunnick J.K. Chromosome 11 allelotypes reflect a mechanism of chemical carcinogenesis in heterozygous p53-deficient mice. Carcinogenesis. 22(1):2001;89-98.
36. Hulla J.E., French J.E., Dunnick J.K. Chromosome 11 loss from thymic lymphomas induced in heterozygous Trp53 mice by phenolphthalein. Toxicol. Sci. 60(2):2001;264-270.
37. de Vries A., Dolle M.E., Broekhof J.L., Muller J.J., Kroese E.D., van Kreijl C.F., Capel P.H., Vijg J., van Steeg H. Induction of DNA adducts and mutations in spleen, liver and lung of XPA-deficient/lacZ transgenic mice after oral treatment with benzo[a]pyrene: correlation with tumour development. Carcinogenesis. 18:1997;2327-2332.
38. de Vries A., van Oostrom C.T., Dortant P.M., Beems R.B., van Kreijl C.F., Capel P.J., van Steeg H. Spontaneous liver tumors and benzo[a]pyrene-induced lymphomas in XPA-deficient mice. Mol. Carcinog. 19:1997;46-53.
39. de Vries A., van Oostrom C.T.M., Hofhius F.M.A., Dortant P.M., Berg F.J.W., de Gruijl F.R., Wester P.W., van Kreijl C.F., Capel P.J.A., van Steeg H., Verbeek S.J. Increased susceptibility to ultraviolet-B and carcinogens of mice lacking the DNA excision repair gene XPA. Nature. 377:1995;169-173.
40. De Vries A., van Steeg H. Xpa knockout mice. Semin. Cancer Biol. 7:1996;229-240.
41. van Steeg H.V., De Vries A., van Oostrom C.T.H., van Benthem J., Beems R., van Kreijl C.F. DNA repair-deficient Xpa and Xpa/p53+/- knockout mice: nature of the models. Toxicol. Pathol. 29(Suppl.):2001;109-116.
42. van Kreijl C.F., McAnulty P.A., Beems R.B., Vynckier A., van Steeg H.F., Fransson-Steen R., Alden C.L., Forster R., van der Laan J.W., Vandenberghe J. Xpa and Xpa/p53+/- knockout mice: overview of available data. Toxicol. Pathol. 29(Suppl.):2001;117-127.
43. Singh V.K., Ganesh L., Cunningham M.L., Shane B.S. Comparison of the mutant frequencies and mutation spectra of three non-genotoxic carcinogens, oxazepam, phenobarbital, and Wyeth 14,643 at the lamda cII locus in Big Blue transgenic mice. Biochem. Pharmacol. 62(6):2001;685-692.
44. Schiestl R.H., Igarashi S., Hastings P.J. Analysis of the mechanism for reversion of a disrupted gene. Genetics. 119(2):1988;237-247.
45. Schiestl R.H. Nonmutagenic carcinogens induce intrachromosomal recombination in yeast. Nature. 337:1989;285-288.
46. Schiestl R.H., Gietz R.D., Mehta R.D., Hastings P.J. Carcinogens induce intrachromosomal recombination in yeast. Carcinogenesis. 10(8):1989;1445-1455.
47. Schiestl R.H., Khogali F., Carls N., Reversion of the mouse pink-eyed unstable mutation induced by low doses of x-rays Science. 266(5190):1994; 1573-1576.
48. Aubrecht J., Rugo R., Schiestl R.H. Carcinogens induce intrachromosomal recombination in human cells. Carcinogenesis. 16:1995;2841-2846.
49. Schiestl R.H., Aubrecht J., Yap W.Y., Kandikonda S., Sidhom S. Polychlorinated biphenyls and 2,3,7,8-tetrachlorodibenzo-p-dioxin induce intrachromosomal recombination in vitro and in vivo. Cancer Res. 57(19):1997;4378-4383.
50. Schiestl R.H., Aubrecht J., Khogali F., Carls N. Carcinogens induce reversion of the mouse pink-eyed unstable mutation. Proc. Natl. Acad. Sci. U.S.A. 94(9):1997;4576-4581.
51. Jalili T., Murthy G.G., Schiestl R.H. Cigarette smoke induces DNA deletions in the mouse embryo. Cancer. Res. 8(12):1998;2633-2638.
52. Bishop J.A., Barlow C., Wynshaw-Boris A.J., Schiestl R.H. Atm deficiency causes an increased frequency of intrachromosomal homologous recombination in mice. Cancer Res. 60(2):2000;395-399.
53. Pritchard J.B., French J.E., Davis B.J., Haseman J.K. The role of transgenic mouse models in carcinogen identification. Environ. Health Perspect. 111(4):2003;444-454.